- Home
- FROG vs ABVX Comparison
FROG vs ABVX Comparison
Compare FROG & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FROG | ABVX |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.9B | 9.0B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | FROG | ABVX |
|---|---|---|
| Price | $62.83 | $125.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 18 | 12 |
| Target Price | $66.00 | ★ $115.83 |
| AVG Volume (30 Days) | ★ 2.0M | 1.8M |
| Earning Date | 02-12-2026 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $502,612,000.00 | $6,231,374.00 |
| Revenue This Year | $24.88 | $6.80 |
| Revenue Next Year | $16.59 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.69 | N/A |
| 52 Week Low | $27.00 | $4.77 |
| 52 Week High | $70.43 | $148.83 |
Technical Indicators
Market Signals| Indicator | FROG | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 50.43 |
| Support Level | $57.58 | $116.20 |
| Resistance Level | $68.38 | $138.69 |
| Average True Range (ATR) | 2.45 | 6.95 |
| MACD | -1.05 | -1.75 |
| Stochastic Oscillator | 53.66 | 40.32 |
Price Performance
Historical ComparisonAbout FROG JFrog Ltd.
JFrog Ltd provides an end-to-end, hybrid, universal DevOps Platform that powers and controls the software supply chain, enabling organizations to continuously and securely deliver software updates across any system. Its product portfolio includes JFrog Artifactory; JFrog Pipelines; JFrog Xray; JFrog Distribution; JFrog Artifactory Edge; JFrog Mission Control and JFrog Insight. Geographically, it derives a majority of revenue from Israel and also has its presence in United States, India and other regions.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.